Federica Urbano

Federica Urbano

Auto-generated profile, based on publicly available information

Federica Urbano

Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MSMarta Schirripa
Marta Schirripa
PBPaola Biason
Paola Biason
SLSara Lonardi
Sara Lonardi
NPNicoletta Pella
Nicoletta Pella
MPMaria Simona Pino
Maria Simona Pino
Matteo FassanMatteo Fassan
Matteo Fassan
Purpose: BRAF mutations are grouped in activating RAS-independent signaling as monomers (class 1–V600E) or as dimers (class 2–codons 597/601), and RAS-dependent with impaired kinase activity (class 3–codons 594/596). Although clinical, pathologic, and molecular features of V600EBRAF-mutated metastatic colorectal cancer (mCRC) are well known, limited data are available from the two other classes.Experimental Design: Data from 117 patients with BRAF (92 class 1, 12 class 2, and 13 class 3)-mutated mCRC were collected. A total of 540 BRAF wt mCRCs were included as control. IHC profiling was performed to determine the consensus molecular subtypes (CMS), cytokeratin 7/20 profiles, tumor-infiltrating lymphocyte infiltration, and BM1/BM2 categorization. Overall survival (OS) and progression-free survival were evaluated by Kaplan–Meier and log-rank test.Results: Class 3 BRAF-mutated mCRC was more frequently left sided (P = 0.0028), pN0 (P = 0.0159), and without peritoneal metastases (P = 0.0176) compared with class 1, whereas class 2 cases were similar to class 1. Hazard ratio for OS, as compared with BRAF wt, was 2.38 [95% confidence interval (CI), 1.61–3.54] for class 1, 1.90 (95% CI, 0.85–4.26) for class 2, and 0.93 (95% CI, 0.51–1.69) for class 3 (P < 0.0001). Class 2 and 3 tumors were all assigned to CMS2-3. A higher median CD3/CD8-positive lymphocyte infiltration was observed in BRAF-mutated class 2 (P = 0.033) compared with class 3 cases.Conclusions: For the first time, different clinical and pathologic features and outcome data were reported according to the three BRAF mutation classes in mCRC. Specific targeted treatment strategies should be identified in the near future for such patients.

1 September 2019 in Surgical Oncology
Verified
Journal Article
Closed access
AGalain gelibter
alain gelibter
SCSalvatore Caponnetto
Salvatore Caponnetto
FUFederica Urbano
Federica Urbano
AEAlessandra Emiliani
Alessandra Emiliani
SSSimone Scagnoli
Simone Scagnoli
ECEnrico Cortesi
Enrico Cortesi

20 May 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SLSara Lonardi
Sara Lonardi
FPFilippo Pietrantonio
Filippo Pietrantonio
APAlessandra Anna Prete
Alessandra Anna Prete
MMMarco Messina
Marco Messina
NRNicola Renzi
Nicola Renzi
VZVittorina Zagonel
Vittorina Zagonel
4051 Background: Advanced squamous cell anal carcinoma (advSCAC) is a rare disease with poor prognosis. No standard therapies beyond first line are currently available, yet a promising activity was documented for the anti-EGFR cetuximab (CET) and for anti-PD-1 agents in previous retrospective case series and phase I-II studies, respectively. In experimental models combination of EGFR and PD-L1 blockade was synergistic as PD-L1 blockade led to NK cells activation enhancing cetuximab ADCC. In this trial we aimed to evaluate safety and activity of the anti-PD-L1 avelumab (AVE) alone or in combination with CET in pretreated advSCAC. Methods: This was an open-label, prospective, multicenter randomized phase 2 trial (NCT03944252). Patients (pts) with advSCAC progressed after at least 1 line of treatment were randomized 1:1 to receive either AVE 10 mg/kg (arm A) or AVE + CET 500 mg/sqm (arm B) as bi-weekly regimens. A Simon’s two-stage Mini-Max design was used. The null hypothesis of a true response rate 5% was tested against the one-sided alternative of a true response rate 20% in each arm. Setting type I error at 0.05 and power at 80%, 30 pts per arm had to be randomized. No formal comparison between the two arms was planned. Primary endpoint was overall response rate (ORR); secondary endpoints were Progression-Free Survival (PFS), Overall Survival (OS) and safety. Results: Sixty pts were enrolled, 30 in each arm. All baseline characteristics were well balanced between the two arms. Median age was 63 years; M/F was 19/41; 12 out of 30 pts in each arm had distant metastases; 7 in arm A and 10 in arm B received > 1 previous lines of treatment. At a median follow up of 8.7 months, 3 out of 30 pts in each arm obtained PR (ORR 10%); SD was observed in 12 pts in arm A (40%) and 14 in arm B (47%). Disease control rate was thus 50% in arm A and 57% in arm B. Duration of disease control was 6.1 (95%CI 3.7–11.0) and 6.1 (95%CI 4.1–9.6) months in arm A and B, respectively. Median PFS was 2.1 (95%CI 1.8–4.0) in arm A and 3.9 months (95%CI 2.1–5.6) in arm B. Grade 3-4 adverse events were 13.3% in arm A and 33.3% in arm B: anemia 10% vs 13.3%, fatigue 0 vs 6.7%, skin toxicity 0 vs 6.7%. Treatment interruption due to AE occurred in 3 pts, 1 in arm A and 2 in arm B. Translational analyses will be performed on tissue and blood samples for exploratory purpose. Conclusions: The CARACAS trial was the first clinical study to test dual EGFR and PD-L1 blockade in advSCAC. Both AVE monotherapy and AVE-CET showed promising activity with manageable safety profile. Clinical trial information: NCT03944252.

31 March 2023
Verified
Other
Open access
MSMarta Schirripa
Marta Schirripa
PBPaola Biason
Paola Biason
SLSara Lonardi
Sara Lonardi
NPNicoletta Pella
Nicoletta Pella
MPMaria Simona Pino
Maria Simona Pino
Matteo FassanMatteo Fassan
Matteo Fassan

31 March 2023
Verified
Other
Open access
MSMarta Schirripa
Marta Schirripa
PBPaola Biason
Paola Biason
SLSara Lonardi
Sara Lonardi
NPNicoletta Pella
Nicoletta Pella
MPMaria Simona Pino
Maria Simona Pino
Matteo FassanMatteo Fassan
Matteo Fassan

31 March 2023
Verified
Other
Open access
MSMarta Schirripa
Marta Schirripa
PBPaola Biason
Paola Biason
SLSara Lonardi
Sara Lonardi
NPNicoletta Pella
Nicoletta Pella
MPMaria Simona Pino
Maria Simona Pino
Matteo FassanMatteo Fassan
Matteo Fassan